TABLE 4.
Use of sulfonylurea drugs and out‐of‐hospital cardiac arrest (OHCA) risk in patients within or outside the context of acute myocardial infarction (AMI)
| Cases | Controls | Crude OR | Adjusted OR | |
|---|---|---|---|---|
| (model 1) | (model 2) | |||
| OHCA‐AMI | 63 | 697 | ||
| Metformin alone | 32 (50.8) | 275 (39.5) | 1.0 (reference) | 1.0 (reference) |
| Sulfonylurea drugs | 31 (49.2) | 422 (60.5) | 0.6 (0.4–1.1) | 0.6 (0.4–1.1) |
| Sulfonylurea drugs alone | 12 (19.0) | 172 (24.7) | 0.6 (0.30–1.2) | 0.6 (0.3–1.2) |
| Sulfonylurea drugs + metformin | 19 (30.2) | 250 (35.9) | 0.6 (0.36–1.2) | 0.7 (0.4–1.2) |
| OHCA‐no AMI | 56 | 697 | ||
| Metformin alone | 26 (46.4) | 275 (39.5) | 1.0 (reference) | 1.0 (reference) |
| Sulfonylurea drugs | 30 (53.6) | 422 (60.5) | 0.7 (0.4–1.3) | 0.7 (0.4–1.2) |
| Sulfonylurea drugs alone | 11 (19.6) | 172 (24.7) | 0.6 (0.3–1.3) | 0.6 (0.3–1.3) |
| Sulfonylurea drugs + metformin | 19 (33.9) | 250 (35.9) | 0.8 (0.4–1.5) | 0.7 (0.4–1.4) |
The immediate cause of OHCA could only obtained for those individuals who survived to hospital admission. Use of metformin and/or sulfonylurea drugs was defined as use within 90 days before the index‐date.
Model 1: OR adjusted for age and sex.
Model 2: OR adjusted for age, sex, use of cardiovascular drugs, Vaughan‐Williams class 1 or 3 antiarrhythmic drugs and non‐cardiac QT‐prolonging drugs.